Download First MRIdian System Installed in Europe at VU University Medical

First MRIdian System Installed in Europe at VU University Medical Center of Amsterdam
March 24, 2016 8:00 AM ET
Patient Treatments with MRI-Guided Radiation Therapy to Begin This Spring
CLEVELAND, March 24, 2016 /PRNewswire/ -- ViewRay, Inc. (OTCQB: VRAY) announced today that the VU
University Medical Center (VUmc) in Amsterdam has installed a MRIdian system, the world's first and only clinical
MRI-guided radiation therapy system, marking the first MRIdian installation in Europe. Patient treatments at VUmc will
commence this Spring.
"MRI guidance is the next big step in radiotherapy and will, for the first time, enable us to adapt the daily treatment plan
and see the tumor and surrounding tissues in real time," said Ben J. Slotman, M.D., Ph.D., professor and chairman
of Radiation Oncology at VUmc.
MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position
and shape of tumors while radiation is delivered. MRIdian is the only clinically-available system in the world that can
provide continuous soft-tissue imaging during radiation treatment. This means that, for the first time, doctors are able to
see the tumor they are treating continuously, enabling personalized and adaptive radiation therapy.
VUmc intends to use the machine for patients with tumors in the abdomen and chest such as bladder cancer, prostate
cancer, renal cancer, pancreatic cancer, rectal cancer, lung cancer and liver metastases. An area of particular interest to the
VUmc team is MRI-guided stereotactic body radiotherapy (SBRT), which is the treatment of cancer using higher doses of
radiation in a shorter course of therapy than traditional radiation therapy.
Earlier this year the radiotherapy department of the VUmc organized an international symposium on SBRT where more
than 240 participants from 26 different countries gathered to listen to leading experts sharing their experience. A part of
the day was dedicated to stereotactic radiotherapy using MRI-guidance, which the center has termed "SMART" for
stereotactic MRI-guided and adaptive radiotherapy.
"Our team has now installed MRIdian systems in each of our major markets – North America, Asia-Pacific, and Europe –
and we congratulate VUmc on their leadership in being the first in Europe," said Chris A. Raanes, president and CEO of
ViewRay Incorporated. "The radiotherapy department of VUmc is known worldwide for its expertise in high-precision
radiotherapy and for being at the forefront of new developments in cancer treatment."
About ViewRay
ViewRay, Inc. of Cleveland, Ohio, is a medical device company that develops advanced radiation therapy technology for
the treatment of cancer. The MRIdian® system provides continuous soft-tissue imaging during treatment, using
MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt
to changes in the patient's anatomy.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements include, among other things, references to the benefits of
MRI guidance and the types of cancers to be treated on the MRIdian at VUmc. Actual results could differ from those
projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to
raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent
uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian linac
technology, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking
Page 1/2
statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all of the information set forth herein and should also refer
to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at
www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-mridian-systeminstalled-in-europe-at-vu-university-medical-center-of-amsterdam-300240952.html
SOURCE ViewRay, Inc.
Michael Saracen, Senior Director, Marketing, ViewRay, Inc., Phone: +1.408.242.2994, Email: [email protected]
Page 2/2